Abstracts tagged "animal models and systemic lupus erythematosus (SLE)"

Abstract Number: 2560 • 2017 ACR/ARHP Annual Meeting
Spleen Tyrosine Kinase Inhibition Reveals Immune Cell Subsets of Diseased NZB/W F1 Mice That Are Reflected in Systemic Lupus Erythematosus Patient Peripheral Blood Mononuclear Cells
Christopher Pohlmeyer¹, Zhi-Hua Cui², Christian Franci¹, Gundula Min-Oo¹, JiYun Kim³ and Julie Di Paolo¹, ¹Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ²Fibrosis Biology, Gilead Sciences, Foster City, CA, ³Biomarkers, Gilead Sciences, Foster City, CA
Background/Purpose: Spleen tyrosine kinase (SYK) is a driver of B cell receptor and Fc receptor signaling pathways, which have central roles in initiating and driving…
Abstract Number: 460 • 2016 ACR/ARHP Annual Meeting
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Demonstrates Anti-Inflammatory Effect in Autoimmune Disease Models
Yohei Yoshiga¹, Fumihito Hosoi¹, Satoru Iguchi¹, Ryuusuke Kaneko¹, Yoshinori Nakachi¹, Daichi Akasaka¹, Kenji Tanaka², Kazuhiko Yonekura², Teruhiro Utsugi², Eiji Sasaki² and Yoshikazu Iwasawa², ¹TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, ²TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: Bruton’s Tyrosine Kinase (BTK), a non-receptor tyrosine kinase is involved in intracellular signaling pathways downstream of several receptors, including the B cell receptor (BCR),…
Abstract Number: 654 • 2014 ACR/ARHP Annual Meeting
Type I Interferon Induces the Depletion and Dysfunction of Endothelial Progenitor Cells in Gld. ApoE-/- C57BL/6 Mice
Linyu Geng¹, Shiying Wang¹, Xuebing Feng² and Lingyun Sun², ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose To study whether the accelerated atherosclerosis in SLE is mediated by type I interferon (IFN-I) through the regulation of endothelial progenitor cells (EPCs) in…
Abstract Number: 557 • 2013 ACR/ARHP Annual Meeting
Inhibition of Calcium/Calmodulin-Dependent Protein Kinase 4 Ameliorates Th17 Related Autoimmune Disorder
Tomohiro Koga¹, Christian Hedrich¹, Masayuki Mizui², Nobuya Yoshida³, Linda Lieberman⁴, José C. Crispin¹ and George C. Tsokos⁵, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: IL-17-producing T helper (Th17) cells have been causally linked to tissue inflammation in several autoimmune diseases including lupus and multiple sclerosis. Blockade of Th17…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].